Table 4.
The micellar NPs based drugs in clinical trials.
| Products | Drugs | Platform | Status | Applications | Refs |
|---|---|---|---|---|---|
| Genexol-PM | Paclitaxel | mPEG-PLA polymeric micelle | Approved | Breast cancer | [167] |
| Lipotecan | Camptothecin analog | Polymeric micelle | Phase I/II | Renal & liver cancers | [168] |
| NC-6004 | Cisplatin | PEG-PGA polymeric micelle | Phase II/III | Genitourinary & gastrointestinal cancers | [169] |
| NK012 | SN-38 | PEG-PGA polymeric micelle | Phase II | Lung, colorectal & ovarian cancers | [78] |
| NK105 | Paclitaxel | PEG-PAA polymeric micelle | Phase II/III | Gastric & breast cancers | [170] |
| NC-6300 | Epirubicin | PEG-b-PAH polymeric micelle | Phase I | Solid tumors | [171] |
| NC-4016 | Oxaliplatin | Polymeric micelle | Phase I | Solid tumors | [172] |
| Paclical | Paclitaxel | Polymeric micelle | Phase III | Ovarian cancer | [173] |
| NK911 | Doxorubicin | PEG-PAA polymeric micelle | Phase I | Solid tumors | [174] |
| SP1049C | Doxorubicin | Pluronic L61 and F 127 polymeric micelle | Phase II/III | Lung cancer | [175] |